文献速递腹部MR

钆塞酸增强MRI肝胆期肝腺瘤亚型的系统评价与荟萃分析

Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
PubMed 文献 · AJR Am J Roentgenol · 2022-08-03

汇总比例总体为14%,HNF1a失活型为0%、未分类型11%、炎症型14%、β-catenin激活型59%,亚型间差异显著。肝胆期等或高信号鉴别FNH与全部肝腺瘤的敏感度99%、特异度89%,但与B-HCA或U-HCA鉴别时特异度仅65%。

要点

  • β-catenin激活型肝腺瘤肝胆期等或高信号比例高达59%,不能据此排除肝腺瘤。
  • HNF1a失活型肝腺瘤肝胆期等或高信号比例约0%,等或高信号基本可排除该亚型。
  • 肝胆期等或高信号鉴别FNH与肝腺瘤总体特异度89%,但与B-HCA/U-HCA鉴别时降至65%。

核心结论

  • 肝腺瘤各亚型肝胆期等或高信号比例从U-HCA的11%到B-HCA的59%不等,B-HCA患病率低是既往报道鉴别FNH与HCA诊断性能高的原因之一。
  • 放射科医生应认识到肝胆期等或高信号鉴别FNH与部分肝腺瘤亚型时特异度较低。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Embase和Cochrane Central Register of Controlled Trials至2022年2月14日。
  • 以病理为参考标准,采用metaregression比较各亚型肝胆期等或高信号汇总比例,并用双变量模型评估诊断性能。

关键影像表现/征象

  • 肝胆期等或高信号汇总比例:全部HCA 14%(95%CI 4-26%),H-HCA 0%(95%CI 0-2%),U-HCA 11%(95%CI 0-29%),I-HCA 14%(95%CI 2-31%),B-HCA 59%(95%CI 26-88%)。
  • metaregression显示各亚型间肝胆期等或高信号比例差异有统计学意义(p < .001)。

诊断标准与关键数值

  • 肝胆期等或高信号鉴别FNH与全部HCA亚型:敏感度99%(95%CI 57-100%),特异度89%(95%CI 82-94%)。
  • 肝胆期等或高信号鉴别FNH与B-HCA或U-HCA:敏感度99%(95%CI 53-100%),特异度65%(95%CI 44-80%)。

临床应用与阅片要点

  • 报告肝胆期等或高信号病灶时,应结合亚型可能性考虑,避免仅凭该征象将B-HCA或U-HCA误判为FNH。
  • 对HNF1a失活型肝腺瘤,肝胆期等或高信号基本不出现,可辅助亚型判断。

局限性

  • 纳入研究包含16项病例报告或病例系列,可能存在选择偏倚。
  • 仅4项研究报告诊断性能信息,诊断性能合并结果基于少量研究。
  • B-HCA样本量较小(33个),其汇总比例置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Accumulating evidence indicates that hepatocellular adenoma (HCA) may have a higher frequency of hepatobiliary phase (HBP) iso- or hyperintensity than previously reported. OBJECTIVE. The purpose of this study was to evaluate the proportion of HCA that shows iso- or hyperintensity in the HBP of gadoxetic acid-enhanced MRI, stratified by HCA subtype (HNF1a-inactivated [H-HCA], inflammatory [I-HCA], β-catenin-activated [B-HCA], and unclassified [U-HCA] HCA), and to assess the diagnostic performance of HBP iso- or hyperintensity for differentiating focal nodular hyperplasia (FNH) from HCA. EVIDENCE ACQUISITION. PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched through February 14, 2022, for articles reporting HBP signal intensity on gadoxetic acid-enhanced MRI among pathologically proven HCAs, stratified by subtype. The pooled proportion of HBP iso- or hyperintensity was determined for each subtype and compared using metaregression. Diagnostic performance of HBP iso- or hyperintensity for differentiating FNH from all HCA subtypes combined and from B-HCA and U-HCA combined was assessed using bivariate modeling. EVIDENCE SYNTHESIS. Twenty-eight studies (12 original investigations, 16 case reports or case series) were included, yielding 364 patients with 410 HCAs (112 H-HCAs, 203 I-HCAs, 33 B-HCAs, 62 U-HCAs). Pooled proportion of HBP iso- or hyperintensity was 14% (95% CI, 4-26%) among all HCAs, 0% (95% CI, 0-2%) among H-HCAs, 11% (95% CI, 0-29%) among U-HCAs, 14% (95% CI, 2-31%) among I-HCAs, and 59% (95% CI, 26-88%) among B-HCAs; metaregression showed significant difference among subtypes (p < .001). In four studies reporting diagnostic performance information, HBP iso- or hyperintensity had sensitivity of 99% (95% CI, 57-100%) and specificity of 89% (95% CI, 82-94%) for differentiating FNH from all HCA subtypes and sensitivity of 99% (95% CI, 53-100%) and specificity of 65% (95% CI, 44-80%) for differentiating FNH from B-HCA or U-HCA. CONCLUSION. HCA subtypes other than H-HCA show proportions of HBP iso- or hyperintensity ranging from 11% (U-HCA) to 59% (B-HCA). Low prevalence of B-HCA has contributed to prior reports of high diagnostic performance of HBP iso- or hyperintensity for differentiating FNH from HCA. CLINICAL IMPACT. Radiologists should recognize the low specificity of HBP iso- or hyperintensity on gadoxetic acid-enhanced MRI for differentiating FNH from certain HCA subtypes.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Kim, Woo, Ebrahimzadeh, et al. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2022. PMID: 35920706. doi:10.2214/AJR.22.27989

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。